Nuvectis Pharma Q2 FY26 net loss widens to USD 7.02 million
NVCT•Q2 results and expense trends
- Nuvectis Pharma posted a GAAP net loss of USD 7.02 million, widening from USD 6.33 million a year earlier.
- R&D expense rose to USD 4.68 million from USD 3.61 million, driven by higher manufacturing, clinical trial costs, and employee compensation.
- G&A expense fell to USD 2.51 million from USD 2.98 million on lower professional and consulting services tied to public company costs.
Cash position and pipeline update
- Cash and cash equivalents totaled USD 22.16 million at June 30, down from USD 31.63 million at Dec. 31; a July follow-on raised USD 115 million gross.
- Nuvectis has in-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; a U.S. pre-IND meeting is planned, with IND submissions targeted for 4Q2026.
